- Home
- HTH vs HCM Comparison
HTH vs HCM Comparison
Compare HTH & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | HCM |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | HTH | HCM |
|---|---|---|
| Price | $34.75 | $13.91 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $13.75 |
| AVG Volume (30 Days) | ★ 314.9K | 19.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | $28.37 |
| Revenue Next Year | $3.07 | $17.50 |
| P/E Ratio | $13.21 | ★ $5.49 |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $27.35 | $11.51 |
| 52 Week High | $40.41 | $19.50 |
Technical Indicators
Market Signals| Indicator | HTH | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 43.61 |
| Support Level | $34.27 | $13.09 |
| Resistance Level | $35.69 | $15.49 |
| Average True Range (ATR) | 0.98 | 0.45 |
| MACD | -0.45 | -0.02 |
| Stochastic Oscillator | 1.68 | 41.59 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.